Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study

L. E. Fox, E. G. MacEwen, I. D. Kurzman, R. R. Dubielzig, S. C. Helfand, D. M. Vail, W. Kisseberth, C. London, B. R. Madewell, C. O. Rodriguez, K. A. Jeglum, M. Rosenberg, R. C. Rosenthal

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p<0.02) and overall survival (p<0.005) when compared with clinical stage III cats.

Original languageEnglish (US)
Pages (from-to)125-130
Number of pages6
JournalCancer Biotherapy
Volume10
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

Felidae
Double-Blind Method
Liposomes
Adenocarcinoma
Cats
Breast
Radical Mastectomy
Therapeutics
Human Mammary Glands
Placebos
mifamurtide
Lipids

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Fox, L. E., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Vail, D. M., ... Rosenthal, R. C. (1995). Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study. Cancer Biotherapy, 10(2), 125-130.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study. / Fox, L. E.; MacEwen, E. G.; Kurzman, I. D.; Dubielzig, R. R.; Helfand, S. C.; Vail, D. M.; Kisseberth, W.; London, C.; Madewell, B. R.; Rodriguez, C. O.; Jeglum, K. A.; Rosenberg, M.; Rosenthal, R. C.

In: Cancer Biotherapy, Vol. 10, No. 2, 1995, p. 125-130.

Research output: Contribution to journalArticle

Fox, LE, MacEwen, EG, Kurzman, ID, Dubielzig, RR, Helfand, SC, Vail, DM, Kisseberth, W, London, C, Madewell, BR, Rodriguez, CO, Jeglum, KA, Rosenberg, M & Rosenthal, RC 1995, 'Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study', Cancer Biotherapy, vol. 10, no. 2, pp. 125-130.
Fox, L. E. ; MacEwen, E. G. ; Kurzman, I. D. ; Dubielzig, R. R. ; Helfand, S. C. ; Vail, D. M. ; Kisseberth, W. ; London, C. ; Madewell, B. R. ; Rodriguez, C. O. ; Jeglum, K. A. ; Rosenberg, M. ; Rosenthal, R. C. / Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study. In: Cancer Biotherapy. 1995 ; Vol. 10, No. 2. pp. 125-130.
@article{2afd0156ec7940659c4d70853f40fd5c,
title = "Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study",
abstract = "Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p<0.02) and overall survival (p<0.005) when compared with clinical stage III cats.",
author = "Fox, {L. E.} and MacEwen, {E. G.} and Kurzman, {I. D.} and Dubielzig, {R. R.} and Helfand, {S. C.} and Vail, {D. M.} and W. Kisseberth and C. London and Madewell, {B. R.} and Rodriguez, {C. O.} and Jeglum, {K. A.} and M. Rosenberg and Rosenthal, {R. C.}",
year = "1995",
language = "English (US)",
volume = "10",
pages = "125--130",
journal = "Cancer Biotherapy",
issn = "1062-8401",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study

AU - Fox, L. E.

AU - MacEwen, E. G.

AU - Kurzman, I. D.

AU - Dubielzig, R. R.

AU - Helfand, S. C.

AU - Vail, D. M.

AU - Kisseberth, W.

AU - London, C.

AU - Madewell, B. R.

AU - Rodriguez, C. O.

AU - Jeglum, K. A.

AU - Rosenberg, M.

AU - Rosenthal, R. C.

PY - 1995

Y1 - 1995

N2 - Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p<0.02) and overall survival (p<0.005) when compared with clinical stage III cats.

AB - Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p<0.02) and overall survival (p<0.005) when compared with clinical stage III cats.

UR - http://www.scopus.com/inward/record.url?scp=0029036470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036470&partnerID=8YFLogxK

M3 - Article

C2 - 7663571

AN - SCOPUS:0029036470

VL - 10

SP - 125

EP - 130

JO - Cancer Biotherapy

JF - Cancer Biotherapy

SN - 1062-8401

IS - 2

ER -